Eyegenex

📍 La Jolla, United States🗓 Founded 2023👥 6 employees💰 Last funded Jul 2025
Pharmaceutical Manufacturing🌐 eyegenex.com
Website LinkedIn
Glaucoma is the leading cause of blindness and is often related to high intraocular pressure. However, over 10% have progressive visual loss despite optimal intraocular pressure lowering. Our drugs are proven to reduce visual loss in animal studies. Non-human primate studies are pending, and human trials will begin in 2025. Diabetic Retinopathy (DR) is caused by damage to blood vessels in the retina of diabetic patients leading to vision loss. Our DR therapeutics are in the early stages of pre-clinical studies
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Eyegenex?
Eyegenex has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Eyegenex last raise funding?
The most recent investment in Eyegenex recorded on gritt.io was in July 2025.
When was Eyegenex founded?
Eyegenex was founded in 2023.
What industry is Eyegenex in?
Eyegenex operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Eyegenex based?
Eyegenex is headquartered in La Jolla, United States.